245 related articles for article (PubMed ID: 25709402)
1. Clinical utility of eslicarbazepine: current evidence.
Zaccara G; Giovannelli F; Cincotta M; Carelli A; Verrotti A
Drug Des Devel Ther; 2015; 9():781-9. PubMed ID: 25709402
[TBL] [Abstract][Full Text] [Related]
2. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy.
Verrotti A; Loiacono G; Rossi A; Zaccara G
Epilepsy Res; 2014 Jan; 108(1):1-10. PubMed ID: 24225327
[TBL] [Abstract][Full Text] [Related]
3. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
5. Eslicarbazepine acetate for partial-onset seizures.
Rauchenzauner M; Luef G
Expert Rev Neurother; 2011 Dec; 11(12):1673-81. PubMed ID: 22091592
[TBL] [Abstract][Full Text] [Related]
6. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
[TBL] [Abstract][Full Text] [Related]
7. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
[TBL] [Abstract][Full Text] [Related]
9. Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.
Lattanzi S; Brigo F; Cagnetti C; Verrotti A; Zaccara G; Silvestrini M
Core Evid; 2018; 13():21-31. PubMed ID: 29563858
[TBL] [Abstract][Full Text] [Related]
10. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
[TBL] [Abstract][Full Text] [Related]
12. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
[TBL] [Abstract][Full Text] [Related]
14. Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy.
Tambucci R; Basti C; Maresca M; Coppola G; Verrotti A
Neuropsychiatr Dis Treat; 2016; 12():1251-60. PubMed ID: 27307737
[TBL] [Abstract][Full Text] [Related]
15. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.
Galiana GL; Gauthier AC; Mattson RH
Drugs R D; 2017 Sep; 17(3):329-339. PubMed ID: 28741150
[TBL] [Abstract][Full Text] [Related]
16. Eslicarbazepine acetate: A novel agent for the adjunctive treatment of epilepsy.
Owen RT
Drugs Today (Barc); 2010 Jan; 46(1):23-31. PubMed ID: 20200693
[TBL] [Abstract][Full Text] [Related]
17. Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy.
Chang XC; Yuan H; Wang Y; Xu HQ; Hong WK; Zheng RY
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD008907. PubMed ID: 34155624
[TBL] [Abstract][Full Text] [Related]
18. Eslicarbazepine Acetate: A Review in Focal-Onset Seizures.
Heo YA
CNS Drugs; 2020 Sep; 34(9):989-1000. PubMed ID: 32737793
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
